On March 16, 2026 Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, reported that Babar K. Rao, MD, FAAD, an internationally recognized academic dermatologist and Principal Investigator of the SKNJCT-003 Phase 2 clinical study, will join the Company’s leadership team during a business update webcast on March 26, 2026 at 11:30 a.m. Eastern time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The SKNJCT-003 study represents a randomized, double-blind Phase 2 clinical trial designed to rigorously evaluate the therapeutic contribution of doxorubicin delivered through the SkinJect microneedle platform in patients with nodular basal cell carcinoma.

The update call will follow the filing of the Company’s Form 10-K for fiscal year 2025, expected after market close on March 25, 2026.

During the call, Dr. Rao will provide clinical interpretation and independent investigator perspective on the recently reported positive dataset from SKNJCT-003.

Basal cell carcinoma (BCC), a highly immunogenic tumor, is the most common cancer worldwide, and SkinJect is designed to provide a minimally invasive treatment option that could potentially reduce the need for surgical excision. The 73% clinical clearance observed in the 200-µg treatment cohort suggests that approximately three (3) out of four (4) treated lesions may achieve visual tumor clearance, potentially allowing many patients to avoid immediate surgical intervention.

Dr. Rao is widely recognized as a leading academic dermatologist, dermatopathologist, and clinical investigator in skin oncology.

He currently serves as:

Professor of Dermatology and Pathology, Rutgers Robert Wood Johnson Medical School
Clinical Associate Professor of Dermatology, Weill Cornell Medical College
Adjunct Professor of Dermatology, California Health Sciences University
Dr. Rao is a board-certified dermatologist and Fellow of the American Academy of Dermatology (FAAD) with decades of experience in dermatologic oncology, dermatopathology, and clinical research.

He completed his dermatology residency and chief residency at Cornell University Medical Center, followed by advanced training at internationally recognized institutions including, New York University Medical Center, Boston University School of Medicine, University of Texas Southwestern Medical Center and St. John’s Institute of Dermatology, University of London.

Dr. Rao has authored more than 200 peer-reviewed scientific publications and multiple academic book chapters and has served as principal investigator in multiple dermatology clinical trials evaluating novel treatments for skin cancer and other dermatologic diseases.

Dr. Rao serves as Principal Investigator of the SKNJCT-003 clinical trial, titled:

"A randomized, double-blind, three-arm Phase 2 study evaluating two dose levels of microneedle-mediated delivery of doxorubicin compared with a device-only control in patients with nodular basal cell carcinoma."

The randomized design of SKNJCT-003, including a device-only control arm, provides a rigorous framework for evaluating the incremental therapeutic contribution of doxorubicin delivered through the SkinJect microneedle system.

The study results demonstrate clear separation in clinical response between the D-MNA treatment arm (73%) and P-MNA treatment arm (38%) in the 200-µg cohort at Day 57, supporting the continued development of SkinJect as a potential non-surgical treatment option for patients with basal cell carcinoma.

The biological activity observed in the device-only arm likely reflects tumor disruption and localized immune activation resulting from microneedle insertion, a phenomenon previously described in intratumoral and microneedle-mediated device studies evaluating solid tumors.

The 200-µg treatment cohort demonstrated the strongest efficacy signal, achieving 73% clinical clearance and 40% histological clearance at Day 57.

Importantly, the magnitude of response observed in the active treatment cohort relative to the device-only control arm provides clinically meaningful evidence of drug-mediated therapeutic effect within a biologically active microneedle delivery platform.

The Company believes the dataset represents decision-grade evidence supporting continued development of the SkinJect program and advancement toward regulatory discussions and potential strategic partnerships.

Corporate Update Call Details

Event: Medicus Pharma Business Update Conference Call
Date: Thursday, March 26, 2026
Time: 11:30 a.m. Eastern Time
Pre-registration: View Source
Dial-in (U.S./Canada) 833-890-6070
Dial-in (international) 412-504-9736
Webcast: View Source

Participants will include:

Dr. Raza Bokhari — CEO & Executive Chairman, Medicus Pharma
Carolyn Bonner—President & CFO. Medicus Pharma
Dr. Babar K. Rao — Principal Investigator, SKNJCT-003
Members of the Medicus executive leadership team
Topics will include:

Financial performance of the company and overview of the business outlook
Clinical interpretation of the SkinJect Phase 2 topline dataset
Investigator perspective on study endpoints and tumor response mechanisms
Development and partnership outlook for the SkinJect program
Development and partnership outlook for the Teverelix Program
Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pre-register can participate by dialing 833-890-6070 (U.S./Canada) or 412-504-9736 (international). A webcast of the call can be accessed.

(Press release, Skinject, MAR 16, 2026, View Source [SID1234663585])